Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mibefradil: a selective T-type calcium antagonist

B M Massie1

  • 1Department of Veterans Affairs Medical Center, San Francisco, California 94121, USA.

The American Journal of Cardiology
|December 31, 1997
PubMed
Summary

Mibefradil, a novel calcium channel blocker, effectively treats hypertension and angina with unique benefits like no negative inotropy. Its potential in heart failure is under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of nesiritide in patients with acute decompensated heart failure.

The New England journal of medicine·2011
Same author

Mode of death in heart failure: findings from the ATLAS trial.

Heart (British Cardiac Society)·2002
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1--the medical history.

Congestive heart failure (Greenwich, Conn.)·2002
Same author

Congestive heart failure with preserved systolic function in a statewide sample of community hospitals.

Journal of cardiac failure·2001
Same author

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.

Archives of internal medicine·2001
Same author

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.

European journal of heart failure·2000

Area of Science:

  • Cardiovascular pharmacology
  • Pharmacology of calcium channel blockers

Background:

  • Mibefradil represents a new class of calcium antagonists.
  • It possesses a unique structure and pharmacology, including selective T-type calcium channel blockade.
  • Mibefradil demonstrates selectivity for smooth muscle over cardiac muscle.

Purpose of the Study:

  • To evaluate the efficacy and safety of mibefradil in treating hypertension and chronic stable angina.
  • To explore the potential benefits of mibefradil in heart failure models.
  • To investigate the novel mechanism of action and pharmacological profile of mibefradil.

Main Methods:

  • Clinical trials comparing mibefradil to diltiazem, amlodipine, and nifedipine for hypertension.
  • Clinical trials assessing mibefradil's efficacy in chronic stable angina against diltiazem and amlodipine.
  • Animal studies using mibefradil in models of ischemia, vascular injury, and heart failure.

Main Results:

  • Mibefradil showed superior or comparable efficacy to existing treatments for hypertension and angina.
  • It increased coronary blood flow, decreased smooth muscle proliferation, and inhibited pathological remodeling in animal models.
  • Mibefradil demonstrated a lack of negative inotropy and reflex tachycardia, and improved survival in a rat heart failure model.

Conclusions:

  • Mibefradil is an effective agent for managing hypertension and angina.
  • Its unique pharmacological profile, including lack of negative inotropic effects and favorable remodeling effects, suggests potential in treating heart failure.
  • Further clinical trials, such as the MACH-1 trial, are investigating its role in congestive heart failure.

Related Experiment Videos